Skip to main content
Premium Trial:

Request an Annual Quote

Luxembourg Provides $1.3M to WaferGen for European Expansion

NEW YORK (GenomeWeb News) – WaferGen Biosystems has received a €1 million ($1.3 million) matching grant from the Luxembourg government to expand its European operations, the company announced after the close of the market on Tuesday.

The first tranche of €350,000 is expected in the first quarter, the Fremont, Calif.-based company said, and will be used to offset startup and personnel costs. WaferGen is recruiting sales, support, and technical personnel and eventually will establish research and diagnostic capabilities in Luxembourg, where its European operation is headquartered.

In a statement, Ivan Trifunovich, president and CEO of WaferGen, said, "This grant will help us expand our European sales activities and enable us to provide regional support and service capabilities."

WaferGen first announced its plans to establish its European operations in Luxembourg in early 2010. Later that year, the company announced a collaboration with the Integrated BioBank of Luxembourg to co-develop molecular signatures for diagnostic research and commercial applications.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.